BioArctic AB’s partner Eisai announced that Eisai has submitted a marketing authorization application for lecanemab, an investigational anti-amyloid beta protofibril[1] antibody, for the treatment of early Alzheimer’s disease[2] with confirmed amyloid pathology in the brain, to the Ministry of Food and Drug Safety in South Korea.
